(Q41558472)

3 October 2017

1 reference

title

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants (English)

1 reference

3 October 2017

0 references

0 references

1 reference

6

1 reference

3 October 2017

von Weizsäcker F

1

1 reference

3 October 2017

Wieland S

2

1 reference

3 October 2017

Köck J

3

1 reference

3 October 2017

Offensperger WB

4

1 reference

3 October 2017

Offensperger S

5

1 reference

3 October 2017

Blum HE

7

1 reference

3 October 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

3 October 2017

1 reference

3 October 2017

volume

26

1 reference

3 October 2017

issue

2

1 reference

3 October 2017

page(s)

251-255

1 reference

The treatment of chronic viral hepatitis

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Exposing the immunology of naked DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Genetic vaccination: the advantages of going naked

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Progress toward human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Human gene therapy comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Hepatic drug delivery and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Nonviral gene therapy: the promise of genes as pharmaceutical products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Simple RNA enzymes with new and highly specific endoribonuclease activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Ribozymes in gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Functional inactivation of genes by dominant negative mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Gene inhibition using antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

A hitchhiker's guide to antisense and nonantisense biochemical pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Transgenes and gene suppression: telling us something new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Inhibition of hepatitis B virus by antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Gene therapy. Intracellular immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Characterization of hepatitis B virus core mutants that inhibit viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

Primary hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Muscle-mediated gene therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.510260237

1 reference

7 January 2021

DNA-based immunization by in vivo transfection of dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Immune responses to plasmid DNA encoding the hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.510260237

1 reference

7 January 2021

Gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Specific regulation of gene expression by antisense, sense and antigene nucleic acids

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Magnesium-mediated conversion of an inactive form of a hammerhead ribozyme to an active complex with its substrate. An investigation by NMR spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510260237

7 January 2021

Identifiers

DOI

10.1002/HEP.510260237

1 reference

3 October 2017

1 reference